Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KPI-001
- Development stage
- Preclinical
- Lead developer
- Kern Pharma
- Administration
- Ophthalmic
01
Overview
KPI-001 is an investigational drug candidate being developed by Kern Pharma for the treatment of endometrial receptivity disorders and female infertility. The project is part of Kern Pharma's research and development pipeline and has received co-financing from the European Regional Development Fund (FEDER) under the Operational Program of Catalonia 2014-2020 (file number RD16-1-0129). While the drug is intended to improve endometrial conditions to support fertility, specific details regarding its active pharmaceutical ingredient, biological target, and modality (such as whether it is a small molecule or a biologic) have not been publicly disclosed by the company.
Beyond the preview
Go deeper on KPI-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KPI-001.